-- Days : -- HRS : -- MIN : -- SEC

Register Now →

Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|April 7, 2025

A Case Study of Elevated Lp(a) Levels and Increased ASCVD Risk

Author(s)Nihar Desai, MD, MPH, Nathan Wong, PhD, Jeremy Wigginton, MD, MBA, FAAFP

Experts discuss an example illustrating the association between lipoprotein(a) (Lp[a]) levels and atherosclerotic cardiovascular disease (ASCVD) risk and explore how this example can inform our understanding of Lp(a) and ASCVD risk on a population level.

Episodes in this series

EP. 1 Lp(a) in ASCVD and Guideline Recommendations

EP. 1 Lp(a) in ASCVD and Guideline Recommendations

EP. 2 Introduction and Burden of Atherosclerotic Disease and Aortic Stenosis

EP. 2 Introduction and Burden of Atherosclerotic Disease and Aortic Stenosis

EP. 3 The Role of Prevention in the Management of Atherosclerotic Disease and Aortic Stenosis

EP. 3 The Role of Prevention in the Management of Atherosclerotic Disease and Aortic Stenosis

EP. 4 Studying the Association Between Elevated Lp(a) Levels and Risk of Atherosclerotic Disease

EP. 4 Studying the Association Between Elevated Lp(a) Levels and Risk of Atherosclerotic Disease

EP. 5 Lp(a) Levels: A Continuous Relationship With ASCVD Levels and Consistent Throughout a Lifetime

EP. 5 Lp(a) Levels: A Continuous Relationship With ASCVD Levels and Consistent Throughout a Lifetime

EP. 6 How the Genetic Nature of Lp(a) Levels Influences Screening

EP. 6 How the Genetic Nature of Lp(a) Levels Influences Screening

EP. 7 A Case Study of Elevated Lp(a) Levels and Increased ASCVD Risk

EP. 7 A Case Study of Elevated Lp(a) Levels and Increased ASCVD Risk

EP. 8 The Role of Management Guidelines in Formulary Decision-Making and Recent Lp(a) Recommendations

EP. 8 The Role of Management Guidelines in Formulary Decision-Making and Recent Lp(a) Recommendations

EP. 9 Evidence Supporting 2024 Guidance for Lp(a) Testing

EP. 9 Evidence Supporting 2024 Guidance for Lp(a) Testing

EP. 10 Factoring Cost, Recommendations, and Evidence Into Formulary Decisions about Lp(a) Testing

EP. 10 Factoring Cost, Recommendations, and Evidence Into Formulary Decisions about Lp(a) Testing

EP. 11 Assessing the Quality of Recommendations and Making Clinical Decisions About Lp(a) Testing

EP. 11 Assessing the Quality of Recommendations and Making Clinical Decisions About Lp(a) Testing

EP. 12 FDA-Approved and Pipeline Treatments for Elevated Lp(a) Levels

EP. 12 FDA-Approved and Pipeline Treatments for Elevated Lp(a) Levels

EP. 13 The Benefits of Lp(a) Testing in the Absence of Lp(a)-Lowering Therapies

EP. 13 The Benefits of Lp(a) Testing in the Absence of Lp(a)-Lowering Therapies

EP. 14 Results of Lp(a) Testing to Modify Risk Assessment and Optimize Treatment

EP. 14 Results of Lp(a) Testing to Modify Risk Assessment and Optimize Treatment

EP. 15 Lp(a) Testing: Prevalence and Strategies to Improve Uptake

EP. 15 Lp(a) Testing: Prevalence and Strategies to Improve Uptake

EP. 16 Implementing Lp(a) Testing in Health Systems: Lessons From Real-World Experience

EP. 16 Implementing Lp(a) Testing in Health Systems: Lessons From Real-World Experience

EP. 17 Implementing Lp(a) Testing: Learning From LDL Testing and Considering Value-Based Care Models

EP. 17 Implementing Lp(a) Testing: Learning From LDL Testing and Considering Value-Based Care Models

EP. 18 Present and Looking to the Future: Lp(a) Testing and Atherosclerotic Disease Management

EP. 18 Present and Looking to the Future: Lp(a) Testing and Atherosclerotic Disease Management

Video content above is prompted by the following:

Dr Wong, can you offer an example illustrating the association between Lp(a) levels and ASCVD risk?
How might Dr Wong’s example inform how we think about Lp(a) and ASCVD risk on a population level?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

maternal health | Image credit: Pituk - stock.adobe.com

CV Health in Pregnancy Linked to Developmental Delay in Children

ByPearl Steinzor

June 23rd 2026

Experts featured in this series.

The Right Fit First: How Psychiatrists Approach Initial Treatment and Patient Adherence

ByPatrick Runnels, MD, MBA,Ginger Shupe, MD,Gus Alva, MD, DFAPA,Joe Goldberg, MD

Published: June 23rd 2026 | Updated: June 16th 2026

Experts featured in this series.

Formulary Frustrations: How Insurance Constraints Shape Psychiatric Treatment Decisions

ByPatrick Runnels, MD, MBA,Ginger Shupe, MD,Gus Alva, MD, DFAPA,Joe Goldberg, MD

Published: June 23rd 2026 | Updated: June 16th 2026

Sandra Chaparro, MD

A Case for SGLT2 Inhibitors in Non-Diabetic CKD: Sandra Chaparro, MD

ByPearl Steinzor,Sandra Chaparro, MD

June 22nd 2026

Navigating the Human Side of Extrapulmonary Neuroendocrine Carcinoma: Patient Burden and Caregiver Support

ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD

June 22nd 2026

Trending on AJMC

Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly

Social Factors May Match, Outpace Genetic Risk in Disease Prediction

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention

Long-Term, Consistent Resistance Training Linked to Substantially Lower Type 2 Diabetes Risk

Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC